Profusa, Inc. received a determination letter from Nasdaq stating that although the company had fewer than 500,000 publicly held shares following its recent 1-for-4 reverse stock split, it complies with the Publicly Held Shares Requirement as of August 21, 2026. Consequently, no further action is required and the listing remains unaffected. Profusa operates in the digital health industry, developing tissue-integrated biosensors for continuous medical data transmission.
